TOURETTE & SEPRANOLONE
COMMERCIAL POTENTIAL
150,000–200,000 treatable population
TREATABLE CHILDREN IN US
A number of peer-reviewed articles(4) have confirmed that the prevalence of Tourette in the Western world is about 0.2 – 0.6%. This means that the treatable population in the US will be some 150,000-200,000 children between the ages of 6-17.
PROFOUND CO-MORBIDITIES
Tourette co-occurs with other mental health or neurodevelopment conditions in over 80% of cases, typically including ASD (Autism Spectrum Disease); ADHD (Attention-Deficit Hyperactivity Disorder) and ADD (Attention Deficit Disorder). Mild SIB (self-injuring behavior) is also thought to affect up to 60% of Tourette patients. In reality therefore market penetration could be relatively low as Tourette patients may already be treated with both CBIT and pharmacological treatment.
Tourette is an orphan indication
Tourette is an orphan disease, and with Sepranolone treatment being efficacious and with none of the serious side effects of competitors, the US market potential is calculated to be approximately 150,000- 200,000 patients, at 35,000 – 52,000 USD per year. Factoring in that many patients may already be treated with CBIT and pharmacological treatment, the market penetration could realistically reach 10% of patients. Resultant peak sales would therefore be approximately 500 – 1,000 MUSD(5).